PTC Therapeutics (PTCT) Misses Q2 EPS by 108c

PTC Therapeutics (NASDAQ: PTCT) reported Q2 EPS of ($2.66), $1.08 worse than the analyst estimate of ($1.58). Revenue for the quarter came in at $213.8 million versus the consensus estimate of $206.84 million.

For earnings history and earnings-related data on PTC Therapeutics (PTCT) click here.

You May Also Be Interested In

• 'Ocean of opportunity': Wolfe initiates SpaceX at Buy ahead of historic IPO
• Citi Assumes PTC Therapeutics (PTCT), Upgrades to Buy
• 51Talk Online Education Group (COE) Reports Q1 EPS of $0.00